@prefix this: <http://purl.org/np/RAwCaWfE1hMqx6htGPRppXMUP7CJnforGUPSSnuHxsmaw> .
@prefix sub: <http://purl.org/np/RAwCaWfE1hMqx6htGPRppXMUP7CJnforGUPSSnuHxsmaw#> .
@prefix drugbank: <http://identifiers.org/drugbank/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix mondo: <http://purl.obolibrary.org/obo/MONDO_> .
@prefix pav: <http://purl.org/pav/> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix ntemplate: <https://w3id.org/np/o/ntemplate/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix pmid: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix ncit: <http://purl.obolibrary.org/obo/NCIT_> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

<http://purl.org/np/RAwCaWfE1hMqx6htGPRppXMUP7CJnforGUPSSnuHxsmaw> a np:Nanopublication;
  np:hasAssertion sub:assertion;
  np:hasProvenance sub:provenance;
  np:hasPublicationInfo sub:pubInfo;
  prov:generatedAtTime "2022-09-16T11:50:11.825168"^^xsd:dateTime;
  prov:wasAttributedTo orcid:0000-0002-1501-1082;
  ntemplate:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .

drugbank:DB01224 a biolink:Drug;
  rdfs:label "Quetiapine";
  biolink:category biolink:Drug .

<http://purl.obolibrary.org/obo/MONDO_0004985> a biolink:Disease;
  rdfs:label "Bipolar disorder";
  biolink:category biolink:Disease .

sub:association a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
  rdf:object <http://purl.obolibrary.org/obo/MONDO_0004985>;
  rdf:predicate biolink:treats;
  rdf:subject drugbank:DB01224;
  rdfs:label "When we asked about the long-term treatment of BD, after having excluded from the analyses the 3 SGAs with a European indication for maintenance BD treatment (aripiprazole, olanzapine, and quetiapine), asenapine was considered either “highly appropriate” or “appropriate” by 44.6% of the respondents, while other off-label SGAs (clozapine, paliperidone, risperidone, ziprasidone) were mostly considered inappro- priate for maintenance bipolar treatment";
  biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
  biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
  biolink:has_population_context sub:context;
  biolink:publications pmid:31291215;
  biolink:relation <http://purl.obolibrary.org/obo/NCIT_C94303> .

sub:context a biolink:Cohort;
  rdfs:label "Adults";
  biolink:category biolink:Cohort .

sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .

sub:sig npx:hasAlgorithm "RSA";
  npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB";
  npx:hasSignature "bEGCe9Y2zrqOV3+ewJI90Z08b10YDbvXuIGxsOSXUmpg2JabO5NQ77t2t0MCkDLx+31xwj5SqDpr4InZh86sTbd0GUw2i7HYSL33yEL9X4aemGWON8QrB3IfzFBI4sBV3LwN1cCNVaGLP6Ip3EvF0PGjL5BicST3qpTXRJKhU2Q=";
  npx:hasSignatureTarget <http://purl.org/np/RAwCaWfE1hMqx6htGPRppXMUP7CJnforGUPSSnuHxsmaw> .

<https://w3id.org/biolink/vocab/> pav:version "2.3.0" .